We are thrilled to announce the finalists for BioBuzz’s 2023 Annual Awards for Greater Philadelphia. Vote now to help us pick the winners. >
And the Finalists Are… Meet BioBuzz’s Greater Philadelphia 2023 Annual Awards Finalists
Give Me Some Space! The Latest on Life Science Lab Spaces in Greater Philadelphia
Give Me Some Space! The Latest on Life Science Lab Spaces in Greater Philadelphia By Mark TerryApril 25, 2023 This section sponsored by ECBuild / EwingCole According to the Winter 2023 Philadelphia Life [….]
Greater Philadelphia Q1 2023 News Recap – Ain’t No Stoppin’ Us Now
Greater Philadelphia Q1 2023 News Recap – Ain’t No Stoppin’ Us Now While times are still rocky, in Q1 Greater Philly showed that it is still very much “on the [….]
Weekly Quick Hits (Greater Philly) – Week of February 27, 2023
Here’s the latest life science news happening out of Greater Philly
Spark Breaks Ground on Gene Therapy Innovation Center on Drexel Campus in Philadelphia, Paving the Way for Future Job Opportunities
Sixteen months since the original announcement, Spark Therapeutics broke ground this week on its Gene Therapy Innovation Center in University City on the Drexel University Campus in Philadelphia. Spark, now a Roche company, developed the first FDA-approved gene therapy, Luxturna. The FDA approved the drug in 2017 to treat patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy.
Five Philly Gene Therapy Companies You Should Know
More than 40 cell and gene therapy companies call Philadelphia home. Their work is facilitated by academic/industrial partnerships with world-class scientists at Children’s Hospital of Philadelphia (CHOP), Temple University, Drexel University, and University of Pennsylvania. Led by Wilson, UPenn’s Gene Therapy Program has been a particularly strong catalyst of the growth that led to $3 billion in investment in cell and gene therapies (CGT) in 2021.
Philadelphia’s Emergence as Life Sciences Hub Creates Mad Dash For Lab Space
By: Jamie Rash, Regional Director, Keystone Development + Investment
Talk about a spark.
When Spark Therapeutics announced plans at the end of last year to develop a $575 million gene therapy manufacturing plant in Philadelphia, it ignited the city’s evolution into a destination for the largest, most innovative life sciences firms in the world.
Over $1 billion in venture capital (VC) investment is pouring into more than 50 Philadelphia life sciences companies that employ some 20,000 people, generating unprecedented demand for lab space. Supply is limited — even with 1 million square feet of lab space in development — and this supply shortage is driving some developers to capitalize on the demand by converting existing building stock.
Jamie Rash, Keystone Development + Investment
Moving Beyond Meds & Eds
Philadelphia is a long-reputed “meds and eds” city, meaning it’s home to anchor institutions of higher learning and world-leading medical facilities that are known for innovation and opportunity. These institutions are major drivers of economic growth throughout the city.
The Promise of Gene Therapy Offers More Hope for Rare Disease Cures in 2022
While the field of gene therapy is still relatively new, it’s moving at a breakneck pace. In fact, 1,745 gene therapies are currently in development around the world! Technological advancements in gene editing, modulation, and replacement technologies have helped to advance this new breed of therapies, raising hope for cures for many of these rare diseases in the near future.
Philadelphia Real Estate Round-Up 2021
In 2021, Philadelphia continued to prove why it’s an up-and-coming life sciences and biotech cluster. Current reports state the city received $1.23 billion in National Institute of Health (NIH) funding in 2021 — and that number is expected to be bigger once finalized, said Lauren Gilchrist, Managing Director of Research at Longfellow Real Estate Partners.
Spark Therapeutics to Invest $575M in New 500k Square Foot State-of-the-Art Gene Therapy Innovation Center on Drexel’s University City Campus
Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced plans to invest an initial $575M in the creation of a new, state-of-the-art gene therapy innovation center on Drexel University’s campus in the heart of Philadelphia’s University City neighborhood.